Literature DB >> 7593178

Immunohistochemical and mutation analyses demonstrate that procollagen VII is processed to collagen VII through removal of the NC-2 domain.

L Bruckner-Tuderman1, O Nilssen, D R Zimmermann, M T Dours-Zimmermann, D U Kalinke, T Gedde-Dahl, J O Winberg.   

Abstract

Collagen VII is the major structural constituent of anchoring fibrils in the skin. It is synthesized as a procollagen that is larger than the collagen deposited in the tissue. In this study, we investigated the conversion of procollagen VII to collagen VII in human skin and in cutaneous cells in vitro and identified the propeptide using domain-specific antibodies. For this purpose, two bacterial fusion proteins containing unique sequences of the carboxy-terminal globular NC-2 domain of procollagen VII were prepared, and polyclonal antibodies raised against them. Immunoblotting showed that the anti-NC2 antibodies reacted with procollagen VII isolated from cultured keratinocytes, but not with collagen VII extracted from the skin. Immunohistochemical experiments with the NC-2 antibodies revealed a strong reaction in cultured keratinocytes, but the basement membrane zone of normal skin remained negative. The staining could not be rendered positive by chemical or enzymatic unmasking of potential hidden epitopes in the skin, indicating that most of the NC-2 domain is absent from normal skin. In contrast, a positive staining with NC-2 antibodies was observed in the skin of a patient with NC-2 antibodies was observed in the skin of a patient with dystrophic epidermolysis bullosa, who carried a 14-bp deletion at one of the intro-exon junctions of the collagen VII gene. This aberration led to an in-frame skipping of exon 115 from the mRNA and eliminated 29 amino acids from the NC-2 domain which include the putative cleavage site for the physiological processing enzyme, procollagen C-proteinase. The results indicate that in normal human skin, the removal of the NC-2 domain from procollagen VII precedes its deposition at the dermal-epidermal junction. Furthermore, they suggest that an aberration in the procollagen VII cleavage interferes with the normal fibrillogenesis of the anchoring fibrils.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7593178      PMCID: PMC2199977          DOI: 10.1083/jcb.131.2.551

Source DB:  PubMed          Journal:  J Cell Biol        ISSN: 0021-9525            Impact factor:   10.539


  25 in total

1.  Tissue form of type VII collagen from human skin and dermal fibroblasts in culture.

Authors:  L Bruckner-Tuderman; U W Schnyder; K H Winterhalter; P Bruckner
Journal:  Eur J Biochem       Date:  1987-06-15

2.  Large complex globular domains of type VII procollagen contribute to the structure of anchoring fibrils.

Authors:  G P Lunstrum; L Y Sakai; D R Keene; N P Morris; R E Burgeson
Journal:  J Biol Chem       Date:  1986-07-05       Impact factor: 5.157

3.  Anchoring fibrils contain the carboxyl-terminal globular domain of type VII procollagen, but lack the amino-terminal globular domain.

Authors:  G P Lunstrum; H J Kuo; L M Rosenbaum; D R Keene; R W Glanville; L Y Sakai; R E Burgeson
Journal:  J Biol Chem       Date:  1987-10-05       Impact factor: 5.157

4.  Truncated profibrillin of a Marfan patient is of apparent similar size as fibrillin: intracellular retention leads to over-N-glycosylation.

Authors:  M Raghunath; C M Kielty; B Steinmann
Journal:  J Mol Biol       Date:  1995-05-19       Impact factor: 5.469

5.  Assessment of procollagen processing defects by fibroblasts cultured in the presence of dextran sulphate.

Authors:  J F Bateman; S B Golub
Journal:  Biochem J       Date:  1990-05-01       Impact factor: 3.857

6.  Differentiating anti-lamina lucida and anti-sublamina densa anti-BMZ antibodies by indirect immunofluorescence on 1.0 M sodium chloride-separated skin.

Authors:  W R Gammon; R A Briggaman; A O Inman; L L Queen; C E Wheeler
Journal:  J Invest Dermatol       Date:  1984-02       Impact factor: 8.551

7.  Type I procollagen C-proteinase from mouse fibroblasts. Purification and demonstration of a 55-kDa enhancer glycoprotein.

Authors:  E Kessler; R Adar
Journal:  Eur J Biochem       Date:  1989-12-08

8.  Molecular characterization of a karyophilic, histone-binding protein: cDNA cloning, amino acid sequence and expression of nuclear protein N1/N2 of Xenopus laevis.

Authors:  J A Kleinschmidt; C Dingwall; G Maier; W W Franke
Journal:  EMBO J       Date:  1986-12-20       Impact factor: 11.598

9.  Epithelial origin of cutaneous anchoring fibrils.

Authors:  S Regauer; G R Seiler; Y Barrandon; K W Easley; C C Compton
Journal:  J Cell Biol       Date:  1990-11       Impact factor: 10.539

10.  Type VII collagen is a major structural component of anchoring fibrils.

Authors:  L Y Sakai; D R Keene; N P Morris; R E Burgeson
Journal:  J Cell Biol       Date:  1986-10       Impact factor: 10.539

View more
  32 in total

1.  Digenic junctional epidermolysis bullosa: mutations in COL17A1 and LAMB3 genes.

Authors:  M Floeth; L Bruckner-Tuderman
Journal:  Am J Hum Genet       Date:  1999-12       Impact factor: 11.025

Review 2.  Metalloproteinases in Drosophila to humans that are central players in developmental processes.

Authors:  Alison Muir; Daniel S Greenspan
Journal:  J Biol Chem       Date:  2011-10-25       Impact factor: 5.157

3.  Characterization of 18 new mutations in COL7A1 in recessive dystrophic epidermolysis bullosa provides evidence for distinct molecular mechanisms underlying defective anchoring fibril formation.

Authors:  A Hovnanian; A Rochat; C Bodemer; E Petit; C A Rivers; C Prost; S Fraitag; A M Christiano; J Uitto; M Lathrop; Y Barrandon; Y de Prost
Journal:  Am J Hum Genet       Date:  1997-09       Impact factor: 11.025

4.  Supramolecular interactions in the dermo-epidermal junction zone: anchoring fibril-collagen VII tightly binds to banded collagen fibrils.

Authors:  Daniela Villone; Anja Fritsch; Manuel Koch; Leena Bruckner-Tuderman; Uwe Hansen; Peter Bruckner
Journal:  J Biol Chem       Date:  2008-07-03       Impact factor: 5.157

5.  Dominant-negative effects of COL7A1 mutations can be rescued by controlled overexpression of normal collagen VII.

Authors:  Anja Fritsch; Sashko Spassov; Susanne Elfert; Andreas Schlosser; Yannick Gache; Guerrino Meneguzzi; Leena Bruckner-Tuderman
Journal:  J Biol Chem       Date:  2009-09-02       Impact factor: 5.157

Review 6.  The bone morphogenetic protein 1/Tolloid-like metalloproteinases.

Authors:  Delana R Hopkins; Sunduz Keles; Daniel S Greenspan
Journal:  Matrix Biol       Date:  2007-05-18       Impact factor: 11.583

7.  Mechanisms of fibroblast cell therapy for dystrophic epidermolysis bullosa: high stability of collagen VII favors long-term skin integrity.

Authors:  Johannes S Kern; Stefan Loeckermann; Anja Fritsch; Ingrid Hausser; Wera Roth; Thomas M Magin; Claudia Mack; Marcel L Müller; Oliver Paul; Patrick Ruther; Leena Bruckner-Tuderman
Journal:  Mol Ther       Date:  2009-06-30       Impact factor: 11.454

8.  Cross-linking of the dermo-epidermal junction of skin regenerating from keratinocyte autografts. Anchoring fibrils are a target for tissue transglutaminase.

Authors:  M Raghunath; B Höpfner; D Aeschlimann; U Lüthi; M Meuli; S Altermatt; R Gobet; L Bruckner-Tuderman; B Steinmann
Journal:  J Clin Invest       Date:  1996-09-01       Impact factor: 14.808

9.  Characterization of molecular mechanisms underlying mutations in dystrophic epidermolysis bullosa using site-directed mutagenesis.

Authors:  David T Woodley; Yingping Hou; Sabrina Martin; Wei Li; Mei Chen
Journal:  J Biol Chem       Date:  2008-04-30       Impact factor: 5.157

10.  A hypomorphic mouse model of dystrophic epidermolysis bullosa reveals mechanisms of disease and response to fibroblast therapy.

Authors:  Anja Fritsch; Stefan Loeckermann; Johannes S Kern; Attila Braun; Michael R Bösl; Thorsten A Bley; Hauke Schumann; Dominik von Elverfeldt; Dominik Paul; Miriam Erlacher; Dirk Berens von Rautenfeld; Ingrid Hausser; Reinhard Fässler; Leena Bruckner-Tuderman
Journal:  J Clin Invest       Date:  2008-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.